Please login to the form below

Not currently logged in

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company
Merck & Co.

Merck & Co has agreed to buy privately-held Scottish biopharma company IOmet in a deal that supplements the pharma group's early-stage cancer immunotherapy pipeline.

Merck (known as MSD outside North America) has not disclosed publicly how much it is paying for Edinburgh-based IOmet, which focuses on a set of molecular pathways that can encourage the immune system to recognise and attack malignant cells, although a BBC report suggested the figure could be as high as £280m.

In particular, IOmet has a preclinical pipeline of compounds that inhibit IDO1 (indoleamine-2,3-dioxygenase 1) and TDO (tryptophan-2,3-dioxygenase) - two enzymes that are often over-expressed in tumour cells, particularly in glioma, melanoma, lung ovarian and colorectal cancers.

When present at high concentrations IDO1 and TDO lead to depletion of a tryptophan, and elevated levels of metabolites such as kynurenine which according to IOmet suppress the immune response. Patients with high IDO1 and TDO tend to have worse prognosis and survival, according to the company.

The first cancer immunotherapy to reach the market was Bristol-Myers Squibb's Yervoy (ipilimumab), which has been joined more recently by BMS' Opdivo (nivolumab) and Merck's Keytruda (pembrolizumab).

Unlike these and other late-stage immuno-oncology candidates, IOmet's IDO1 and TDO inhibitors are small-molecule drugs so could be orally-active.  
Other companies working in this area include Incyte, which has IDO1 inhibitor epacadostat in clinical trials, and has previously said it intends to start a combination trial with Keytruda in melanoma later this year.

NewLink Genetics also has trials of a candidate called indoximod ongoing in a range of cancers and forged a $250m alliance with Genentech for follow-up compound GDC-0919 in 2014.

Meanwhile, BMS also bought into the area via its $1.2bn purchase of Flexus last year, which included an IDO/TDO discovery programme.

IOmet also has a programme looking at the role of inhibiting the glucose transporter (GLUT1), which is also over-expressed in cancer cells and is linked to more aggressive disease and reduced patient survival time, and has a GLUT9 inhibitor programme in gout.

IOmet will become a wholly owned subsidiary of Merck after the transaction goes through, according to Merck.

IOmet's chief executive Alan Wise said becoming part of Merck "creates significant opportunity for us to advance the treatment of cancer."

Article by
Phil Taylor

13th January 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...